RU2012145278A - Трансдермальное введение пептидов - Google Patents
Трансдермальное введение пептидов Download PDFInfo
- Publication number
- RU2012145278A RU2012145278A RU2012145278/15A RU2012145278A RU2012145278A RU 2012145278 A RU2012145278 A RU 2012145278A RU 2012145278/15 A RU2012145278/15 A RU 2012145278/15A RU 2012145278 A RU2012145278 A RU 2012145278A RU 2012145278 A RU2012145278 A RU 2012145278A
- Authority
- RU
- Russia
- Prior art keywords
- cys
- thr
- lys
- phe
- trp
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 20
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 24
- 239000000194 fatty acid Substances 0.000 claims abstract 24
- 229930195729 fatty acid Natural products 0.000 claims abstract 24
- -1 fatty acid salt Chemical class 0.000 claims abstract 17
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract 8
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims abstract 8
- 150000004665 fatty acids Chemical class 0.000 claims abstract 7
- 150000003839 salts Chemical group 0.000 claims abstract 5
- 102000005157 Somatostatin Human genes 0.000 claims abstract 4
- 108010056088 Somatostatin Proteins 0.000 claims abstract 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims abstract 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims abstract 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960000553 somatostatin Drugs 0.000 claims abstract 4
- 230000037317 transdermal delivery Effects 0.000 claims abstract 4
- 229940044601 receptor agonist Drugs 0.000 claims abstract 3
- 239000000018 receptor agonist Substances 0.000 claims abstract 3
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims abstract 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims abstract 2
- 108050001286 Somatostatin Receptor Proteins 0.000 claims abstract 2
- 102000011096 Somatostatin receptor Human genes 0.000 claims abstract 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims abstract 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- HZUFJLNYZNGZLC-UHFFFAOYSA-N 6-amino-n-[1-[[1-[(1-amino-3-hydroxy-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2-[[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1h-indol-3-y Chemical compound C=1NC2=CC=CC=C2C=1CC(NC(=O)C(CC=1C=CC(O)=CC=1)NC(=O)C(CC=1C=CC(Cl)=CC=1)NC(=O)C(N)CC=1C=CC=CC=1)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(N)=O)CC1=CC=CC=C1 HZUFJLNYZNGZLC-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940123051 Somatostatin receptor agonist Drugs 0.000 abstract 2
- DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 abstract 1
- 108010069495 cysteinyltyrosine Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20100174A IE20100174A1 (en) | 2010-03-25 | 2010-03-25 | Transdermal administration of peptides |
| IE2010/0174 | 2010-03-25 | ||
| PCT/IE2011/000019 WO2011117851A1 (en) | 2010-03-25 | 2011-03-23 | Transdermal administration of peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012145278A true RU2012145278A (ru) | 2014-04-27 |
Family
ID=44210069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012145278/15A RU2012145278A (ru) | 2010-03-25 | 2011-03-23 | Трансдермальное введение пептидов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130085105A1 (enExample) |
| EP (1) | EP2550005A1 (enExample) |
| JP (1) | JP2013523629A (enExample) |
| KR (1) | KR20130062275A (enExample) |
| CN (1) | CN102883735A (enExample) |
| AU (1) | AU2011231173A1 (enExample) |
| BR (1) | BR112012022377A2 (enExample) |
| CA (1) | CA2792470A1 (enExample) |
| IE (1) | IE20100174A1 (enExample) |
| MX (1) | MX2012010343A (enExample) |
| RU (1) | RU2012145278A (enExample) |
| WO (1) | WO2011117851A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665401A (zh) | 2009-11-16 | 2012-09-12 | 益普生制药股份有限公司 | 黑皮质素受体配体的药物组合物 |
| WO2011115871A1 (en) * | 2010-03-15 | 2011-09-22 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
| SI2568806T1 (sl) | 2010-05-12 | 2016-09-30 | Radius Health, Inc. | Režimi zdravljenja |
| AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| TWI662967B (zh) * | 2013-03-25 | 2019-06-21 | 日商志瑞亞新藥工業股份有限公司 | 食後期之胃運動亢進劑 |
| PT3122426T (pt) | 2014-03-28 | 2023-02-28 | Univ Duke | Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio |
| US10266579B2 (en) | 2014-09-14 | 2019-04-23 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Synthetic somatostatin receptor ligands |
| EP3288383A4 (en) | 2015-04-29 | 2019-01-23 | Radius Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| HRP20220619T1 (hr) | 2016-06-22 | 2023-02-03 | Ellipses Pharma Ltd | Postupci za liječenje ar+ raka dojke |
| ES2981967T3 (es) | 2017-01-05 | 2024-10-14 | Radius Pharmaceuticals Inc | Formas polimórficas de RAD1901-2HCl |
| KR101786914B1 (ko) * | 2017-01-31 | 2017-11-15 | 주식회사 삼양사 | 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드 |
| CN107226840A (zh) * | 2017-05-04 | 2017-10-03 | 西安交通大学 | 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用 |
| CA3076751A1 (en) * | 2017-09-26 | 2019-04-04 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
| WO2019236603A1 (en) * | 2018-06-08 | 2019-12-12 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
| JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形形態 |
| IT201800009384A1 (it) * | 2018-10-11 | 2020-04-11 | Cosmo Srl | Peptide for cosmetic application |
| JOP20210218A1 (ar) | 2019-02-12 | 2023-01-30 | Radius Pharmaceuticals Inc | عمليات ومركبات |
| DE102020130492A1 (de) * | 2020-11-18 | 2022-05-19 | Lts Lohmann Therapie-Systeme Ag. | Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle |
| WO2023281447A1 (en) * | 2021-07-07 | 2023-01-12 | Radius Health, Inc. | Methods of treating a cardiovascular ischemic event |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954975A (en) * | 1972-02-17 | 1976-05-04 | Ciba-Geigy Corporation | Salts of ACTH-peptides and processes for their manufacture |
| IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
| JPH08505367A (ja) * | 1992-10-16 | 1996-06-11 | スミスクライン・ビーチャム・コーポレイション | 医薬用エマルジョン組成物 |
| US6316414B1 (en) * | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| CA2450446A1 (en) * | 2001-06-25 | 2003-01-03 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| AU2002340120A1 (en) * | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| WO2006040447A1 (fr) * | 2004-10-07 | 2006-04-20 | L'oreal | Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase |
| US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
| EP2001518B1 (en) * | 2006-03-30 | 2013-07-10 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| JP5231412B2 (ja) * | 2006-07-11 | 2013-07-10 | キューピーエス リミテッド ライアビリティ カンパニー | ペプチドを持続的放出により送達するための薬理組成物 |
| GB0705264D0 (en) * | 2007-03-20 | 2007-04-25 | Pliva Istrazivanje I Razvoj D | Gel forming compounds |
| US20100196264A1 (en) * | 2007-05-18 | 2010-08-05 | The Brigham And Women's Hospital, Inc. | Use of somatostatin analogs in myocardial perfusion imaging |
| WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
-
2010
- 2010-03-25 IE IE20100174A patent/IE20100174A1/en not_active IP Right Cessation
-
2011
- 2011-03-23 RU RU2012145278/15A patent/RU2012145278A/ru not_active Application Discontinuation
- 2011-03-23 JP JP2013500647A patent/JP2013523629A/ja not_active Ceased
- 2011-03-23 AU AU2011231173A patent/AU2011231173A1/en not_active Abandoned
- 2011-03-23 US US13/637,244 patent/US20130085105A1/en not_active Abandoned
- 2011-03-23 MX MX2012010343A patent/MX2012010343A/es not_active Application Discontinuation
- 2011-03-23 EP EP11712680A patent/EP2550005A1/en not_active Withdrawn
- 2011-03-23 CN CN2011800157799A patent/CN102883735A/zh active Pending
- 2011-03-23 KR KR1020127027694A patent/KR20130062275A/ko not_active Withdrawn
- 2011-03-23 WO PCT/IE2011/000019 patent/WO2011117851A1/en not_active Ceased
- 2011-03-23 BR BR112012022377A patent/BR112012022377A2/pt not_active IP Right Cessation
- 2011-03-23 CA CA2792470A patent/CA2792470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012022377A2 (pt) | 2017-01-10 |
| CN102883735A (zh) | 2013-01-16 |
| US20130085105A1 (en) | 2013-04-04 |
| KR20130062275A (ko) | 2013-06-12 |
| IE20100174A1 (en) | 2012-02-29 |
| WO2011117851A1 (en) | 2011-09-29 |
| MX2012010343A (es) | 2013-01-29 |
| JP2013523629A (ja) | 2013-06-17 |
| EP2550005A1 (en) | 2013-01-30 |
| CA2792470A1 (en) | 2011-09-29 |
| AU2011231173A1 (en) | 2012-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012145278A (ru) | Трансдермальное введение пептидов | |
| JP2013523629A5 (enExample) | ||
| ES2486675T3 (es) | Análogo de péptido de oxintomodulina | |
| MX2011002783A (es) | Rapalogos, composiciones farmaceuticas, metodos de preparacion y usos de los mismos. | |
| CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
| CL2004001602A1 (es) | Compuestos no esteroidales derivados de propionanilida, moduladores del receptor androgenico con selectividad tisular (sarm); composicion farmaceutica; y uso en el tratamiento o prevencion de condiciones dependientes del receptor androgenico, como hi | |
| WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
| AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
| AR076706A1 (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| ECSP034430A (es) | Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios | |
| EP2583976A3 (en) | Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens | |
| CL2008003848A1 (es) | Compuestos derivados de fenilo o heteroarilo bis-sulfonilamino sustituidos, inhibidores de prostaglandina e sintasa-1 microsomal; composicion farmaceutica; procedimiento de preparacion; procedimiento de preparacion de la composicion farmaceutica; y uso en el tratamiento del dolor agudo o cronico, dolor nociceptivo o dolor neuropatico. | |
| MX2008002345A (es) | Formulaciones inyectables de larga accion. | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| BR122016022033B8 (pt) | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica | |
| CL2007002188A1 (es) | Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal. | |
| ATE534383T1 (de) | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid | |
| PE20141219A1 (es) | Profarmaco de adrenomedulina basado en polietilenglicol y su uso | |
| CR20170070A (es) | Composición, método y preparación del ácido biliar sintético | |
| BR112012006579A2 (pt) | agonistas de npr-b. | |
| EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
| EP2486916A8 (en) | Human growth hormone formulations | |
| ITMI20052461A1 (it) | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive | |
| WO2011076209A3 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| EA200601279A1 (ru) | Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150916 |